金石亚药(300434) - 2023年5月19日投资者关系活动记录表

Group 1: Company Overview - Sichuan Jinshi Asia Pharmaceutical Co., Ltd. is a leading brand in the cold medicine market with products like "Kuaike" and "Xiaokuaike" [3][6] - The company has five main production bases covering over 400 acres, ensuring stable and efficient production capacity [3][7] - The company adheres to strict quality assurance systems, complying with GMP and GSP standards, ensuring product quality stability [3][4] Group 2: Financial Performance - As of March 31, 2022, the number of shareholders was 22,085 [5][12] - In Q1 2023, the company achieved a revenue of 420 million yuan and a net profit of 143 million yuan [5][14] - The revenue from the pharmaceutical manufacturing sector was approximately 1.09 billion yuan, accounting for 87.47% of total revenue [12][14] Group 3: Product Development and Innovation - The company is focusing on enhancing existing products and expanding its product line in respiratory and pediatric precision medications [2][3] - Ongoing research includes the development of high-end traditional Chinese medicine products and innovative formulations [3][7] - The company has initiated projects for new drug development, including consistency evaluation and generic drug projects [5][14] Group 4: Marketing and Sales Strategy - The marketing network includes 1,200 chain stores and approximately 92,000 cooperative pharmacies, covering over 90% of cities and 70% of counties in China [4][6] - The company is leveraging both online and offline channels to enhance brand visibility and consumer engagement [4][6] - A dedicated marketing team of over 1,000 members supports the sales of the "Kuaike" brand through established relationships with distribution channels [4][6] Group 5: Risk Management - The company acknowledges potential risks in market, policy, and operational aspects and is committed to building a robust risk prevention and response system [3][4] - The management emphasizes maintaining operational independence from major shareholders to protect the interests of minority shareholders [8][12]